Cortexin, 10 mg, 5 ml, 10 pcs.

Composition

1 bottle of lyophilizate contains:

Active ingredient:

cortexin (complex of water-soluble polypeptide fractions) 10 mg,

auxiliary substance:

vglycine (stabilizer) 12 mg

Pharmacological action

CORTEXIN contains a complex of low-molecular-weight water-soluble polypeptide fractions that penetrate the blood-brain barrier directly to nerve cells. The drug has nootropic, neuroprotective, antioxidant and tissue-specific effects. Nootropic – improves higher brain functions, learning and memory processes, concentration of attention, stability under various stressful influences.

Neuroprotective – protects neurons from damage by various endogenous neurotoxic factors (glutamate, calcium ions, free radicals), reduces the toxic effects of psychotropic substances.

Antioxidant – inhibits lipid peroxidation in neurons, increases the survival rate of neurons under conditions of oxidative stress and hypoxia. Tissue-specific – activates the metabolism of neurons of the central and peripheral nervous system, reparative processes, improves the functions of the cerebral cortex and the overall tone of the nervous system.

Mechanism of action

CORTEXIN is caused by activation of neuron peptides and neurotrophic factors of the brain; optimization of the balance of metabolism of excitatory and inhibitory amino acids, dopamine, serotonin; GABAergic effect; reduction of paroxysmal convulsive brain activity, the ability to improve its bioelectric activity; prevention of the formation of free radicals (products of lipid peroxidation).

Pharmacokinetics

The composition of CORTEXIN, the Active ingredient of which is a complex of polypeptide fractions, does not allow for the usual pharmacokinetic analysis of individual components.

Indications

In complex therapy:

• brain circulatory disorders;
• TBI and its consequences;
• encephalopathies of various origins;
• cognitive disorders (memory and thinking disorders);
• acute and chronic encephalitis and encephalomyelitis;
• epilepsy;
• asthenic conditions (suprasegmental vegetative disorders);
• reduced learning ability;
• delayed psychomotor and speech development in children;
• various forms of cerebral palsy.

Contraindications

Individual intolerance to the drug.

The drug is contraindicated during pregnancy (due to the lack of data from clinical studies).

If it is necessary to prescribe the drug during lactation, breastfeeding should be discontinued (due to the lack of data from clinical studies).

Side effects

No side effects were reported.

Individual hypersensitivity to the components of the drug is possible.

How to take, course of administration and dosage

The drug is administered intramuscularly.

The contents of the vial before injection are dissolved in 1-2 ml of 0.5% procaine (novocaine) solution, water for injection or 0.9% sodium chloride solution, directing the needle to the wall of the vial to avoid foaming, and administered once daily: adults at a dose of 10 mg for 10 days; children with a body weight of up to 20 kg at a dose of 0.5 mg/kg, with a body weight of more than 20 kg-at a dose of 10 mg for 10 days.

If necessary, repeat the course in 3-6 months. In case of hemispheric ischemic stroke in the acute and early recovery periods, adults should take a dose of 10 mg 2 times a day (morning and afternoon) for 10 days, with a second course after 10 days.

Form of production

Lyophilizate for the preparation of a solution for intramuscular administration

Storage conditions

Store in a dry place, protected from light, at a temperature of 2-20 °C

Shelf life

3 years

Active ingredient

Cattle cortical polypeptides

Conditions of release from pharmacies

By prescription

Dosage form

solution for injection

Weight

Weight: 91 g.